Accordingly, Buchner et al. [43] demonstrated that CXCR4 antagonists abrogate the stromal cell-induced protection of CLL cells and, thereby, increase the efficacy of rituximab-induced CDC. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.